Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN 3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/3qg1FWzZRI

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK

National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB

Survey shows only 1% of men are concerned about bone density; but 2 million men have osteoporosis, and 16 million men have osteopenia. https://t.co/DA4vSmj0vd? https://t.co/V4OChN022V

Increasing costs of biologics. X-sectional study of 76 781 psoriasis pts on biologics (TNFi, IL12/23, IL-17i, IL-23i) saw annual treatment cost increase from $21 236 in 2007 to $47 125 in 2021. AVG cost could have been 44% lower if lowest-cost Rx in same class was used https://t.co/IOaK75zsgg

By March 2025, the FDA has approved 71 biosimilars (15 interchangeable). The US & EU biosimilars markets spent $22.58 billion in 2024 & is projected to increase by 25% to $171.79 billion by 2033 https://t.co/fsqGTzWuhC https://t.co/ZLYSIwRqI4

EULAR 2025 – RA Panel Discussion Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN

Eular 2025 PsA Topic Panel https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76

EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes. https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6

UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) & 311 SI deaths. MTX signif decr. SI (adj HR 0.72) & CS no effect HR 0.99. SI assoc w/ age, smoker, comorbidity, seropositive, high DAS28. 1 DAS unit incr SI https://t.co/Zmsuaf7Rw3

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY